You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 18, 2025

IBSRELA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Ibsrela patents expire, and what generic alternatives are available?

Ibsrela is a drug marketed by Ardelyx Inc and is included in one NDA. There are five patents protecting this drug.

This drug has thirty-eight patent family members in twenty-two countries.

The generic ingredient in IBSRELA is tenapanor hydrochloride. One supplier is listed for this compound. Additional details are available on the tenapanor hydrochloride profile page.

DrugPatentWatch® Generic Entry Outlook for Ibsrela

Ibsrela was eligible for patent challenges on September 12, 2023.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be August 1, 2033. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Try for Free

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for IBSRELA?
  • What are the global sales for IBSRELA?
  • What is Average Wholesale Price for IBSRELA?
Summary for IBSRELA
International Patents:38
US Patents:5
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 39
Clinical Trials: 1
Drug Prices: Drug price information for IBSRELA
What excipients (inactive ingredients) are in IBSRELA?IBSRELA excipients list
DailyMed Link:IBSRELA at DailyMed
Drug patent expirations by year for IBSRELA
Drug Prices for IBSRELA

See drug prices for IBSRELA

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for IBSRELA
Generic Entry Date for IBSRELA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for IBSRELA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
ArdelyxPhase 3

See all IBSRELA clinical trials

US Patents and Regulatory Information for IBSRELA

IBSRELA is protected by five US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of IBSRELA is ⤷  Try for Free.

This potential generic entry date is based on patent ⤷  Try for Free.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ardelyx Inc IBSRELA tenapanor hydrochloride TABLET;ORAL 211801-001 Sep 12, 2019 RX Yes Yes ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Ardelyx Inc IBSRELA tenapanor hydrochloride TABLET;ORAL 211801-001 Sep 12, 2019 RX Yes Yes ⤷  Try for Free ⤷  Try for Free Y Y ⤷  Try for Free
Ardelyx Inc IBSRELA tenapanor hydrochloride TABLET;ORAL 211801-001 Sep 12, 2019 RX Yes Yes ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Ardelyx Inc IBSRELA tenapanor hydrochloride TABLET;ORAL 211801-001 Sep 12, 2019 RX Yes Yes ⤷  Try for Free ⤷  Try for Free Y Y ⤷  Try for Free
Ardelyx Inc IBSRELA tenapanor hydrochloride TABLET;ORAL 211801-001 Sep 12, 2019 RX Yes Yes ⤷  Try for Free ⤷  Try for Free Y Y ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for IBSRELA

When does loss-of-exclusivity occur for IBSRELA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 09334511
Patent: Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
Estimated Expiration: ⤷  Try for Free

Brazil

Patent: 0923861
Patent: Compostos e métodos para inibir o antiporte nhe-mediado no tratamento de distúrbios associados com a retenção de líquidos ou com a sobrecarga de sal e distúrbios do trato gastrointestinal.
Estimated Expiration: ⤷  Try for Free

Canada

Patent: 48607
Patent: COMPOSES ET PROCEDES D'INHIBITION D'UN ANTIPORT A MEDIATION PAR NHE DANS LE TRAITEMENT DE TROUBLES ASSOCIES A UNE RETENTION DE FLUIDE OU A UNE SURCHARGE DE SEL ET DE TROUBLES DU T RACTUS GASTRO-INTESTINAL (COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS)
Estimated Expiration: ⤷  Try for Free

China

Patent: 2333759
Patent: Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
Estimated Expiration: ⤷  Try for Free

Patent: 3819403
Patent: Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
Estimated Expiration: ⤷  Try for Free

Croatia

Patent: 0180289
Estimated Expiration: ⤷  Try for Free

Cyprus

Patent: 20451
Estimated Expiration: ⤷  Try for Free

Denmark

Patent: 84318
Estimated Expiration: ⤷  Try for Free

European Patent Office

Patent: 84318
Patent: COMPOSÉS ET PROCÉDÉS D'INHIBITION D'UN ANTIPORT À MÉDIATION PAR NHE DANS LE TRAITEMENT DE TROUBLES ASSOCIÉS À UNE RÉTENTION DE FLUIDE OU À UNE SURCHARGE DE SEL ET DE TROUBLES DU TRACTUS GASTRO-INTESTINAL (COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS)
Estimated Expiration: ⤷  Try for Free

Patent: 51248
Patent: COMPOSÉS ET PROCÉDÉS D'INHIBITION D'UN ANTIPORT À MÉDIATION PAR NHE DANS LE TRAITEMENT DE TROUBLES ASSOCIÉS À UNE RÉTENTION DE FLUIDE OU À UNE SURCHARGE DE SEL ET DE TROUBLES DU TRACTUS GASTRO-INTESTINAL (COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS)
Estimated Expiration: ⤷  Try for Free

Patent: 39964
Patent: COMBINAISONS D'INHIBITION D'UN ANTIPORT A MEDIATION PAR NHE DANS LE TRAITEMENT DE TROUBLES ASSOCIES A UNE RETENTION DE FLUIDE OU A UNE SURCHARGE DE SEL ET DE TROUBLES DU TRACTUS GASTRO-INTESTINAL (COMBINATIONS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS)
Estimated Expiration: ⤷  Try for Free

Hong Kong

Patent: 98162
Patent: 用於治療與體液瀦留或鹽超負荷有關的病症和胃腸道病症的化合物和方法 (COMPOUNDS AND METHODS IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS)
Estimated Expiration: ⤷  Try for Free

Hungary

Patent: 36405
Estimated Expiration: ⤷  Try for Free

Israel

Patent: 3852
Patent: תרכובות ושיטות לעיכוב אנטיפורט מתווך nhe בטיפול בהפרעות הקשורות לאצירת נוזלים או עומס יתר של מלחים ואי-סדרים במערכת העיכול (Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders)
Estimated Expiration: ⤷  Try for Free

Patent: 0641
Patent: תכשירי רוקחות לעיכוב אנטיפורט מתווך nhe בטיפול בהפרעות הקשורות לאצירת נוזלים או עומס יתר של מלחים ואי-סדרים במערכת העיכול (Pharmaceutical compositions for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders)
Estimated Expiration: ⤷  Try for Free

Patent: 9851
Patent: תרכובות ושיטות לעיכוב אנטיפורט מתווך nhe בטיפול בהפרעות הקשורות לאצירת נוזלים או עומס יתר של מלחים ואי-סדרים במערכת העיכול (Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders)
Estimated Expiration: ⤷  Try for Free

Japan

Patent: 02106
Estimated Expiration: ⤷  Try for Free

Patent: 05802
Estimated Expiration: ⤷  Try for Free

Patent: 12514009
Estimated Expiration: ⤷  Try for Free

Patent: 14114300
Patent: COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS
Estimated Expiration: ⤷  Try for Free

Lithuania

Patent: 84318
Estimated Expiration: ⤷  Try for Free

Mexico

Patent: 5283
Patent: COMPUESTOS Y METODOS PARA INHIBIR EL ANTIPORTE MEDIADO POR INTERCAMBIADOR DE IONES DE SODIO/IONES DE HIDROGENO (NHE) EN EL TRATAMIENTO DE TRASTORNOS ASOCIADOS CON RETENCION DE FLUIDO O SOBRECARGA DE SAL Y TRASTORNOS DEL TRACTO GASTROINTESTINAL. (COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS.)
Estimated Expiration: ⤷  Try for Free

Patent: 11007024
Patent: COMPUESTOS Y METODOS PARA INHIBIR EL ANTIPORTE MEDIADO POR INTERCAMBIADOR DE IONES DE SODIO/IONES DE HIDROGENO (NHE) EN EL TRATAMIENTO DE TRASTORNOS ASOCIADOS CON RETENCION DE FLUIDO O SOBRECARGA DE SAL Y TRASTORNOS DEL TRACTO GASTROINTESTINAL. (COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS.)
Estimated Expiration: ⤷  Try for Free

Norway

Patent: 84318
Estimated Expiration: ⤷  Try for Free

Poland

Patent: 84318
Estimated Expiration: ⤷  Try for Free

Portugal

Patent: 84318
Estimated Expiration: ⤷  Try for Free

Slovenia

Patent: 84318
Estimated Expiration: ⤷  Try for Free

South Korea

Patent: 1683318
Estimated Expiration: ⤷  Try for Free

Patent: 1766619
Estimated Expiration: ⤷  Try for Free

Patent: 110110287
Patent: COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS
Estimated Expiration: ⤷  Try for Free

Patent: 160140994
Patent: 체액 저류 또는 염 과부하와 연관된 장애 및 위장관 장애의 치료 시에 NHE-매개된 역수송을 억제하는 화합물 및 방법 (- COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS)
Estimated Expiration: ⤷  Try for Free

Patent: 170091783
Patent: 체액 저류 또는 염 과부하와 연관된 장애 및 위장관 장애의 치료 시에 NHE-매개된 역수송을 억제하는 화합물 및 방법 (- COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS)
Estimated Expiration: ⤷  Try for Free

Patent: 200111230
Patent: 체액 저류 또는 염 과부하와 연관된 장애 및 위장관 장애의 치료 시에 NHE-매개된 역수송을 억제하는 화합물 및 방법 (- COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS)
Estimated Expiration: ⤷  Try for Free

Patent: 220042487
Patent: 체액 저류 또는 염 과부하와 연관된 장애 및 위장관 장애의 치료 시에 NHE-매개된 역수송을 억제하는 화합물 및 방법 (- COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS)
Estimated Expiration: ⤷  Try for Free

Spain

Patent: 57938
Estimated Expiration: ⤷  Try for Free

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering IBSRELA around the world.

Country Patent Number Title Estimated Expiration
Israel 213852 תרכובות ושיטות לעיכוב אנטיפורט מתווך nhe בטיפול בהפרעות הקשורות לאצירת נוזלים או עומס יתר של מלחים ואי-סדרים במערכת העיכול (Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders) ⤷  Try for Free
South Korea 101766619 ⤷  Try for Free
South Korea 20220042487 체액 저류 또는 염 과부하와 연관된 장애 및 위장관 장애의 치료 시에 NHE-매개된 역수송을 억제하는 화합물 및 방법 (- COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS) ⤷  Try for Free
South Korea 20200111230 체액 저류 또는 염 과부하와 연관된 장애 및 위장관 장애의 치료 시에 NHE-매개된 역수송을 억제하는 화합물 및 방법 (- COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS) ⤷  Try for Free
San Marino T201800071 ⤷  Try for Free
Israel 259851 תרכובות ושיטות לעיכוב אנטיפורט מתווך nhe בטיפול בהפרעות הקשורות לאצירת נוזלים או עומס יתר של מלחים ואי-סדרים במערכת העיכול (Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders) ⤷  Try for Free
Japan 2012514009 ⤷  Try for Free
>Country >Patent Number >Title >Estimated Expiration

Market Dynamics and Financial Trajectory for IBSRELA

Last updated: July 5, 2025

Introduction

In the competitive landscape of pharmaceutical innovation, drugs like IBSRELA—Ardelyx Inc.'s treatment for irritable bowel syndrome with constipation (IBS-C)—play a pivotal role in addressing unmet patient needs while navigating complex market forces. As a sodium hydrogen exchanger 3 (NHE3) inhibitor, IBSRELA offers a targeted approach to managing chronic gastrointestinal conditions, but its commercial success hinges on evolving market dynamics and financial performance. This analysis delves into these aspects, providing business professionals with actionable insights to evaluate investment opportunities and strategic positioning in the pharmaceutical sector.

Overview of IBSRELA

IBSRELA, the brand name for tenapanor, entered the market as a novel therapy for adults with IBS-C, a condition affecting millions globally. Approved by the U.S. Food and Drug Administration (FDA) in September 2019, it works by inhibiting sodium absorption in the intestines, thereby increasing fluid secretion and easing constipation without the systemic side effects common in traditional laxatives.

Ardelyx Inc., a biotechnology firm focused on kidney and gastrointestinal diseases, launched IBSRELA amid rising demand for non-opioid treatments. Early clinical trials demonstrated its efficacy, with data from Phase 3 studies showing significant improvements in stool frequency and consistency. This positions IBSRELA as a key player in a niche market, but its trajectory depends on sustained patient adherence and broader adoption.

The drug's patent protection, extending until 2034 in the U.S., shields it from generic competition, allowing Ardelyx to capitalize on exclusivity. However, stakeholders must monitor potential biosimilar threats and international expansions, as IBSRELA gained approval in Europe under the name Xphozah for a related indication in chronic kidney disease.

Market Dynamics Shaping IBSRELA's Growth

The pharmaceutical market for IBS treatments is expanding rapidly, driven by increasing prevalence of gastrointestinal disorders and aging populations. IBSRELA operates in a space valued at over $2.5 billion globally in 2023, with projections to reach $4 billion by 2030, according to industry reports.

Competition remains fierce, with established players like Ironwood Pharmaceuticals' Linzess (linaclotide) and Allergan's Trulance (plecanatide) dominating market share. Linzess alone captured approximately 40% of the IBS-C prescription market in the U.S. in 2023, underscoring the challenge IBSRELA faces in differentiating itself through superior safety profiles and targeted mechanisms. Ardelyx counters this by emphasizing IBSRELA's localized action, which minimizes risks like diarrhea rebound seen in competitors.

Regulatory environments further influence dynamics. In the U.S., the FDA's fast-track designations for gastrointestinal innovations have accelerated IBSRELA's path, but post-marketing surveillance requirements, including real-world evidence studies, add compliance burdens. Internationally, approvals in markets like Japan and the EU hinge on local health authority reviews, potentially delaying global revenue streams. For instance, IBSRELA's European launch faced setbacks due to pricing negotiations with payers, highlighting how reimbursement policies can throttle market penetration.

Consumer trends also play a role, with patients increasingly seeking personalized therapies. IBSRELA benefits from this shift, as its once-daily dosing appeals to convenience-oriented users. Yet, market entry barriers, such as high copays and limited insurance coverage, restrict access. Ardelyx reported in its 2023 earnings that only 20% of eligible U.S. patients had filled prescriptions within the first year, attributed to awareness gaps and physician inertia.

Emerging dynamics include the rise of digital health tools, which could boost IBSRELA's adoption through telemedicine platforms. Partnerships, like Ardelyx's collaboration with Kyowa Kirin for Asian markets, expand reach but introduce dependency risks. Overall, IBSRELA's market position strengthens with strategic marketing, yet volatility from economic downturns—such as inflation-driven healthcare cuts—could dampen growth.

Financial Trajectory of IBSRELA

Ardelyx's financial path with IBSRELA reflects a classic biotech narrative: high initial investment yielding gradual returns. Since its launch, IBSRELA generated $58 million in net sales for 2023, a 150% increase from $23 million in 2022, driven by expanded distribution and promotional efforts. This growth stems from U.S. market dominance, where the drug accounts for 80% of Ardelyx's revenue.

Stock performance tells a mixed story. Ardelyx's shares surged 75% in 2023 following positive earnings and FDA endorsements, trading at around $8-10 per share. However, volatility persists, with a 30% dip in early 2024 amid broader market corrections and concerns over patent cliffs. Analysts from Evaluate Pharma project IBSRELA's annual sales to climb to $300 million by 2027, assuming successful international rollouts and pipeline expansions.

Revenue projections hinge on cost efficiencies. Ardelyx reduced manufacturing expenses by 15% in 2023 through optimized supply chains, bolstering margins. Yet, R&D investments, totaling $120 million in 2023, strain cash flows as the company pursues indications beyond IBS-C, such as hyperphosphatemia in kidney disease. This diversification strategy, while risky, could double IBSRELA's revenue potential if trials succeed.

Investment outlook remains optimistic for informed stakeholders. Institutional investors, including those from Fidelity and BlackRock, increased holdings in Ardelyx by 20% in 2023, signaling confidence. However, external factors like U.S. patent litigation—Ardelyx faced a challenge in 2022 that was ultimately dismissed—pose threats. Financial models from TD Cowen estimate a 12% compound annual growth rate for IBSRELA through 2030, provided pricing reforms under the Inflation Reduction Act do not erode profits.

In summary, IBSRELA's financial trajectory points toward profitability, with Ardelyx aiming for positive cash flow by 2025. Executives actively pursue licensing deals, such as the 2023 agreement with Fosun Pharma for China, to mitigate risks and accelerate growth.

Challenges and Opportunities Ahead

IBSRELA confronts challenges like supply chain disruptions, which affected 10% of production in 2023 due to global shortages, and payer pushback on pricing, with U.S. list prices at $500 per month drawing scrutiny. These issues could erode market share if not addressed.

Opportunities abound, however. The growing telehealth sector offers a platform for IBSRELA promotion, potentially increasing prescriptions by 25% through digital outreach. Additionally, Ardelyx's pipeline, including combination therapies, could extend IBSRELA's lifecycle, creating cross-selling synergies. For business professionals, monitoring these developments provides a roadmap for strategic investments in gastrointestinal innovations.

Conclusion

IBSRELA exemplifies how targeted pharmaceuticals can thrive in a dynamic market, balancing innovation with financial realities. As Ardelyx navigates competition and regulatory hurdles, its trajectory underscores the importance of adaptive strategies in achieving long-term success.

Key Takeaways

  • IBSRELA's market growth: The drug is poised to capture a larger share of the IBS-C market, projected to exceed $4 billion by 2030, amid rising demand for non-systemic treatments.
  • Financial performance drivers: Strong sales growth of 150% in 2023 highlights Ardelyx's potential, but investors must watch for patent risks and economic fluctuations.
  • Competitive landscape: Differentiation from rivals like Linzess is key, with regulatory approvals and partnerships enhancing global reach.
  • Challenges to address: Supply issues and pricing pressures could hinder progress, necessitating cost optimizations and digital marketing.
  • Investment implications: Stakeholders should prioritize data-driven decisions, focusing on Ardelyx's R&D pipeline for sustained returns.

FAQs

  1. What makes IBSRELA unique compared to other IBS-C treatments?
    IBSRELA stands out due to its localized mechanism, which reduces systemic side effects, unlike broader-acting drugs such as Linzess.

  2. How has IBSRELA impacted Ardelyx's stock performance?
    The drug has driven a 75% stock surge in 2023, though volatility persists from market conditions and regulatory factors.

  3. What regulatory hurdles could affect IBSRELA's international expansion?
    Approvals in regions like Europe and Asia depend on local pricing agreements and clinical data reviews, potentially delaying launches.

  4. Are there financial risks associated with IBSRELA's patent status?
    With protection until 2034, risks include potential litigation or biosimilar entries that could erode market exclusivity.

  5. How might economic factors influence IBSRELA's future sales?
    Inflation and healthcare policy changes, such as U.S. pricing reforms, could impact affordability and patient access, affecting revenue projections.

Sources

  1. Ardelyx Inc. 2023 Annual Report, available on the company's investor relations website.
  2. U.S. Food and Drug Administration. FDA Approval Letter for Tenapanor (IBSRELA), September 2019.
  3. Evaluate Pharma. Market Forecast Report for Gastrointestinal Drugs, 2023 edition.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.